Bladder Cancer

Use cystoscopic tumor documentation and TURBT pathology to assign local stage and grade. Record tumor size, multiplicity, location, appearance, prior recurrence history, prior intravesical treatment, and whether carcinoma in situ is present; these variables determine NMIBC recurrence and progression risk and guide intravesical versus definitive surgical management. Wolters Kluwer+2Wolters KluwerDefinitions, End Points, and Clinical Trial... : Journal of Clinical OncologyScienceDirectRecurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy - ScienceDirectauajournalsDiagnosis and Treatment of Non-Muscle Invasive Bladder ...

Confirm whether the TURBT specimen demonstrates Ta disease, lamina propria-invasive T1 disease, carcinoma in situ, or muscularis propria invasion. T1 high-grade disease and carcinoma in situ carry materially greater progression concern than low-grade papillary disease; carcinoma in situ is particularly important for risk stratification after grade. ScienceDirect+1ScienceDirectNon Muscle Invasive Treatment of Bladder Cancer - an overview | ScienceDirect TopicsPubMedThe management of BCG failure in non-muscle-invasive bladder cancer: an update

For suspected or established muscle-invasive disease, obtain cross-sectional staging imaging as part of the initial evaluation. Before TURBT, pelvic MRI or CT urogram is preferred in trial-staging frameworks because TURBT-related inflammation can cause local overstaging; chest CT is also used for baseline staging. Wolters Kluwer+1Wolters KluwerDefinitions, End Points, and Clinical Trial... : Journal of Clinical OncologyauajournalsTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)

After TURBT, use pathology and endoscopic burden to separate low-grade papillary disease from high-grade Ta, T1 high-grade, and carcinoma in situ. Most NMIBC presents as Ta, with smaller proportions presenting as T1 or carcinoma in situ, but the latter patterns drive progression risk and need for intensive intravesical treatment or early cystectomy discussion. ScienceDirect+1ScienceDirectRecurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy - ScienceDirectPubMedThe management of BCG failure in non-muscle-invasive bladder cancer: an update

For high-risk NMIBC, TURBT followed by intravesical BCG is standard treatment. BCG reduces recurrence compared with TURBT alone and has demonstrated superior recurrence-free outcomes versus several intravesical chemotherapeutic regimens in high-risk disease. The Lancet+1The LancetPembrolizumab monotherapy for the treatment of high-risk ...PubMedBCG in Bladder Cancer Immunotherapy - PMC

Counsel patients with the highest-risk NMIBC features regarding radical cystectomy as an oncologically definitive alternative to BCG-based preservation. In high-risk T1 disease and/or carcinoma in situ that fails BCG, progression risk has been reported as high as 50%; immediate cystectomy offers the best survival opportunity but carries major quality-of-life consequences related to urinary diversion and loss of the native bladder. auajournals+1auajournalsPredicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center CohortPubMedThe management of BCG failure in non-muscle-invasive bladder cancer: an update

For clinically non-metastatic muscle-invasive bladder cancer, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the reference curative-intent pathway. Meta-analytic evidence indicates that neoadjuvant cisplatin-based treatment reduces mortality risk by 13% and yields an absolute 5-year survival benefit of approximately 5%. PubMedPubMedImmune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review

Perform radical cystectomy with bilateral pelvic lymphadenectomy when surgery is selected. TURBT remains essential for diagnosis and local debulking, but a pathologic response after neoadjuvant chemotherapy cannot be attributed entirely to chemotherapy because complete TURBT can independently downstage some tumors. ScienceDirect+1ScienceDirectPathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? - ScienceDirectauajournalsTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)

Offer bladder-preserving trimodality therapy to patients seeking preservation when multidisciplinary assessment supports it. The regimen combines maximal TURBT, concurrent chemotherapy, and radiation therapy; radiation alone and maximal TURBT alone are not equivalent bladder-preserving curative strategies. auajournalsauajournalsTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)

For clinically node-positive bladder urothelial carcinoma, initiate multiagent systemic therapy and reassess candidacy for intensive local treatment. In observational data, high-intensity local therapy—radical cystectomy with pelvic lymph-node dissection or bladder radiation of at least 50 Gy with TURBT—combined with systemic chemotherapy was associated with improved survival compared with conservative local treatment; selection should account for baseline life expectancy and treatment response. ScienceDirectScienceDirectHigh-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival - ScienceDirect

The optimal approach for cN+ or limited retroperitoneal nodal disease remains uncertain because these patients are often excluded from definitive-treatment trials. Cisplatin-based chemotherapy followed by cystectomy with pelvic lymph-node dissection is commonly used, while trimodality therapy is an option for patients choosing bladder preservation. PubMedPubMedThe Role of Radical Cystectomy And Lymphadenectomy In The Management Of Bladder Cancer With Clinically Positive Lymph Node Involvement

For stage IV or M1 disease, prioritize systemic therapy. Listed systemic options include enfortumab vedotin plus pembrolizumab, chemotherapy combined with immunotherapy, chemotherapy alone, or immunotherapy; use external-beam radiation, diversion, or cystectomy for palliation of uncontrolled local symptoms or as selected adjunctive local treatment. PubMedPubMedBladder Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf

For NMIBC efficacy assessment frameworks, perform cystoscopy and urine cytology every 3 months and CT or MRI urography at 6- to 12-month intervals. Use blue-light or other advanced cystoscopy consistently if it was used at baseline; changing technique between examinations can confound interpretation of apparent response or recurrence. Wolters KluwerWolters KluwerDefinitions, End Points, and Clinical Trial... : Journal of Clinical Oncology

Do not perform routine random or bladder-mapping biopsies at fixed intervals as standard care in either BCG-naive or BCG-unresponsive NMIBC. A random bladder biopsy at 12 months is an optional trial-design measure for high-risk NMIBC, not a universal surveillance mandate. Wolters KluwerWolters KluwerDefinitions, End Points, and Clinical Trial... : Journal of Clinical Oncology

Escalate from surveillance to repeat TURBT, directed biopsy, or definitive-treatment counseling when cystoscopy identifies recurrent lesions, cytology suggests occult high-grade disease, or pathology demonstrates persistent high-grade T1 disease or carcinoma in situ after BCG. The purpose of repeat tissue assessment is to avoid misclassifying progressive disease as a manageable superficial recurrence. Wolters Kluwer+2Wolters KluwerDefinitions, End Points, and Clinical Trial... : Journal of Clinical OncologyauajournalsDiagnosis and Treatment of Non-Muscle Invasive Bladder ...PubMedThe management of BCG failure in non-muscle-invasive bladder cancer: an update